Unlock instant, AI-driven research and patent intelligence for your innovation.

CD19 antibodies and their uses

An antibody and application technology, applied in the field of CD19 antibody and its application, can solve the problem of human anti-mouse and other problems

Inactive Publication Date: 2012-06-27
ER SQUIBB & SONS INC
View PDF101 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A disadvantage of using murine antibodies to treat human subjects is the development of human anti-mouse (HAMA) responses after administration to patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD19 antibodies and their uses
  • CD19 antibodies and their uses
  • CD19 antibodies and their uses

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0353] Preparation of human monoclonal antibody-producing hybridomas

[0354] To prepare hybridomas that produce the human monoclonal antibodies of the present invention, spleen cells and / or lymph node cells are isolated from the immunized mice and fused with a suitable immortalized cell line (e.g., a mouse myeloma cell line). The hybridomas obtained are screened based on the production of antigen-specific antibodies. For example, 50% PEG can be used to fuse a single cell suspension of splenic lymphocytes from immunized mice with one-sixth the number of P3X63-Ag8.653 nonsecreting mouse myeloma cells (ATCC, CRL 1580). Alternatively, a CytoPulse large chamber cell fusion electroporator (CytoPulse Sciences, Inc., Glen Burnie Maryland) can be used to fuse a single cell suspension of splenic lymphocytes from immunized mice using an electric field-based electrofusion method. Divide the cells to approximately 2×10 5 The density was inoculated in a flat-bottomed microtiter plate, and th...

Embodiment 1

[0440] Example 1: Preparation of anti-CD19 human monoclonal antibody

[0441] antigen

[0442] B-cell tumor cell lines Raji (ATCC deposit number CCL-86) and Daudi (ATCC deposit number CCL-213) were used as antigens for immunization.

[0443] Transgenic transchromosome KM-mouse

[0444] A fully human monoclonal antibody against CD19 was prepared using transgenic transchromosomal KM mice expressing human antibody genes. In this mouse line, the endogenous mouse kappa light chain gene has been homozygously disrupted as described in Chen et al. (1993) EMBO J.12: 811-820, and has been implemented as described in PCT Publication WO 01 / 09187 Example 1 homozygously destroys the endogenous mouse heavy chain gene for HuMab mice. The mouse carries the human kappa light chain transgene KCo5, as described in Fishwild et al. (1996) Nature Biotechnology 14:845-851. This mouse also carries the human heavy chain transchromosome SC20, as described in PCT Publication WO 02 / 43478.

[0445] KM-mouse Im...

Embodiment 2

[0453] Example 2: Structural characterization of human monoclonal antibodies 21D4, 21D4a, 47G4, 27F3, 3C10, 5G7, 13F1 and 46E8

[0454] The cDNA sequences of the heavy and light chain variable regions of monoclonal antibodies encoding 21D4 and 21D4a were obtained from 21D4 hybridomas using standard PCR technology, and sequenced using standard DNA sequencing technology. Note that the 21D4 hybridoma produces antibodies in which the heavy chain is paired with one of the two light chains (SEQ ID NOs: 8 and 9). Two antibodies (ie V with SEQ ID NOs: 1 and 8 respectively H And V L 21D4 of the sequence, and V with SEQ ID NOs: 1 and 9, respectively H And V L The 21D4a) of the sequence binds to CD19. The cDNA sequences encoding the heavy and light chain variable regions of the 47G4, 27F3, 3C10, 5G7, 13F1, and 46E8 monoclonal antibodies were obtained from 21D4, 21D4a, 47G4, 27F3, 3C10, 5G7, 13F1, and 46E8 hybridomas using standard PCR techniques, respectively. Obtained and sequenced using ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.

Description

[0001] Cross reference of related applications [0002] This application requires the U.S. Provisional Patent Application No. 60 / 692,531 filed on June 20, 2005, the U.S. Provisional Patent Application No. 60 / 748,956 filed on December 8, 2005, and the U.S. Provisional Patent filed on June 6, 2006 Application No. 60 / 804,083 rights; all of these applications are incorporated herein by reference in their entirety. Background of the invention [0003] CD19 is a 95kDa membrane receptor, which is expressed in the early stage of B cell differentiation and continues to express until the B cell is triggered to final differentiation (Pezzutto et al. (1987). J. Immunol. 138: 2793; Tedder et al. (1994) Immunol. Today 15: 437). The extracellular domain of CD19 contains two C2-type immunoglobulin (IG)-like domains separated by a smaller potential disulfide bond-linked domain. The CD19 cytoplasmic domain is unique in structure, but is highly conserved among humans, mice, and guinea pigs (Fujimot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28A61P35/00A61P35/02
Inventor C·拉奥-奈克D·J·金刘劼黄海春D·B·帕斯莫尔A·F·贝尔J·M·卡达雷利C·潘T·U·蒂·多S·陈D·M·塔纳玛奇
Owner ER SQUIBB & SONS INC